Latin American Society for Immunodeficiencies - LASID,
https://www.ncbi.nlm.nih.gov/pubmed/29043014
https://www.ncbi.nlm.nih.gov/pubmed/29043014
https://www.ncbi.nlm.nih.gov/pubmed/29043014
Lanadelumab long-term safety and efficacy in preventing #HAE attacks: a new openlabel extension study #CTA_journal https://ctajou…
Lanadelumab, a new subcutaneous and self-administred prophylactic therapy might improve efficacy, safety and tolerability in #her…